Pancreas News and Research

RSS

The pancreas is a gland organ in the digestive and endocrine system of vertebrates. It is both an endocrine gland producing several important hormones, including insulin, glucagon, and somatostatin, as well as an exocrine gland, secreting pancreatic juice containing digestive enzymes that pass to the small intestine. These enzymes help in the further breakdown of the carbohydrates, protein, and fat in the chyme.

FDA accepts BMY and AstraZeneca's dapagliflozin NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.

9 Mar 2011

Lab made urinary tube going strong after six years of transplant

In a scientific breakthrough, five boys who were unable to urinate due to pelvic injury were cured for up to six years after getting new lab-grown urethras or urinary tubes that connect with the bladder. This breakthrough comes from Wake Forest University researcher Anthony Atala. It was in 2006 that the team reported the first successful implantation of lab-grown urinary bladders into humans. Today six years after the operation all of the boys continue to do well, with normal or near-normal urinary flow. The boy first treated is now 16 years old and received his lab-grown urethra over six years ago.

8 Mar 2011

First western U.S. hand transplant surgery performed at UCLA Medical Center

Surgeons at Ronald Reagan UCLA Medical Center performed the first hand transplant in the western United States in an operation that began one minute before midnight on Friday, March 4, and was completed 14-and-a-half hours later, on Saturday, March 5.

8 Mar 2011

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2010.

5 Mar 2011

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante Pharmaceuticals, Inc. today announced publication of results from a Phase II clinical study that show BioSante's Pancreas Cancer Vaccine increased the median survival of resected pancreatic cancer patients from 15 to 20 months, as reported in published data, to 24.8 months, an increase of more than 25 percent.

4 Mar 2011

New colon cancer screening campaign initiative in New York City

In honor of National Colon Cancer Awareness Month, Katie Couric, the New York City Department of Health and Mental Hygiene, WCBS-TV and The Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian Hospital announced the launch of the "Make That Call" for colon cancer screening campaign.

2 Mar 2011

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Endoscopic removal of pre-cancerous cells in patients with confirmed, high-risk Barrett's esophagus is recommended rather than surveillance, according to a new "Medical Position Statement on the Management of Barrett's Esophagus," published by the American Gastroenterological Association (AGA) Institute. The medical position statement was published in Gastroenterology, the official journal of the AGA Institute.

1 Mar 2011

Researchers discover new mechanism of beta cell destruction not previously known

The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.

28 Feb 2011

Study: More effective therapies needed for diabetes patients with ESRD

Despite significant advances in kidney care over the past 20 years, efforts to improve therapy for type 1 diabetes patients with kidney dysfunction remain unsuccessful, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that more effective therapies are needed for these patients.

24 Feb 2011

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.

18 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes

The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study period in this trial. This important achievement in the Diamyd® Phase III program will now be followed by an intense period where the data will be compiled from the more than 60 clinics throughout Europe and from the central laboratory.

14 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

Dream Foundation to fulfill final dream for Stage III Pancreatic Cancer patient

On February 6, Dream Foundation, the first national wish-granting organization for adults in the end stages of life, will fulfill Ed Demyan's final dream - to witness the ultimate American sporting event, the Super Bowl. Demyan, 47, of Brooklyn, Ohio, is a proud father three daughters (11, 14, 22) and a future step-daughter (15).

5 Feb 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the second quarter ended December 31, 2010.

5 Feb 2011

Viewpoints: Judge Vinson's decision and Sarah Palin, Voting Rights Act; States' Medicaid 'burden;' Global fund controversy

With news coverage focused on Federal District Judge Roger Vinson's decision Monday to declare the health care reform law unconstitutional, it might be easy to miss this week's news from another federal courthouse: opponents of the Voting Rights Act have renewed their efforts to have that law declared unconstitutional, too.

5 Feb 2011

Researchers identify regulatory defect that drives lupus

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.

3 Feb 2011

Pancreas News and Research

Further Reading

FDA accepts BMY and AstraZeneca's dapagliflozin NDA for review

Lab made urinary tube going strong after six years of transplant

First western U.S. hand transplant surgery performed at UCLA Medical Center

Redpoint Bio fourth quarter revenues are $0.7 million for 2010

BioSante vaccine increases median survival of resected pancreatic cancer patients

New colon cancer screening campaign initiative in New York City

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Researchers discover new mechanism of beta cell destruction not previously known

Study: More effective therapies needed for diabetes patients with ESRD

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Last patient in EU Diamyd Phase III clinical study completes 15-month visit for type 1 diabetes

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Repligen third quarter total revenue increases 26% to $7,068,000

Dream Foundation to fulfill final dream for Stage III Pancreatic Cancer patient

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Viewpoints: Judge Vinson's decision and Sarah Palin, Voting Rights Act; States' Medicaid 'burden;' Global fund controversy

Researchers identify regulatory defect that drives lupus

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News